Revenues

3 Months Ended

Mar. 31, 2022

Revenues

Revenues

Note 3.     Revenues

Revenues are recognized under guidance within ASC 606, Revenue from Contracts with Customers. The following table presents our disaggregated revenue for the periods presented (in thousands):

	Three Months Ended
	March 31,
	2022		2021
JAKAFI revenues, net	$	544,464	$	465,710
ICLUSIG revenues, net		26,069		25,645
PEMAZYRE revenues, net		18,032		13,456
MINJUVI revenues, net		4,502		—
OPZELURA revenues, net		12,754		—
Total product revenues, net		605,821		504,811
JAKAVI product royalty revenues		70,867		65,602
OLUMIANT product royalty revenues		48,064		32,258
TABRECTA product royalty revenues		3,483		2,047
Total product royalty revenues		122,414		99,907
Milestone and contract revenues		5,000		—
Total revenues	$	733,235	$	604,718

For further information on our revenue-generating contracts, refer to Note 7.